A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 69
- Population
- ALL · 50 Years
- Duration
- 2022-08-23 to 2028-08-01
- Intervention
- ADVM-022
- Comparator
- Not reported
- Outcomes measured
- Incidence of ocular and non-ocular adverse events — Up to Week 52; Severity of ocular and non-ocular adverse events — Up to Week 52; Mean change in best corrected visual acuity (BCVA) from Baseline — Baseline up to Week 52; Percentage of participants from Baseline who lose/gain at least 5, 10 or 15 letters in BCVA — Baseline up to 5 years; Mean change in BCVA from Baseline — Baseline up to 5 years; Percentage of participants who are supplemental aflibercept injection-free — Baseline up to 5 years; Percent reduction in annualized anti-VEGF injections — Baseline up to 5 years; Mean change in Central Subfield Thickness (CST) from Baseline — Baseline up to 5 years; Percentage of participants without CST fluctuations — Baseline up to 5 years; Mean number of CST fluctuations from Baseline — Baseline up to 5 years; Percentage of participants without post-prophylactic inflammation — Baseline up to 5 years; Incidence of ocular and non-ocular adverse events — Up to 60 months; Severity of ocular and non-ocular adverse events — Up to 60 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.